Amber Ophthalmics is a clinical stage biopharmaceutical company focused on ocular drug development. 
 
Since forming in 2020, the company has aspired to be a leader in the development of novel therapeutics through scientific innovation, addressing unmet ophthalmic medical needs.

Amber Ophthalmics is focused on the development of its current clinical asset NEXAGON and continued expansion of the drug development pipeline through acquisition.  Amber is pursuing in-licensing programs that leverage emerging technologies, such as gene therapies, antibodies, bispecifics, peptides, and oligonucleotides.

The Amber team was formed following the successful drug approval and subsequent transaction of another San Diego based company. 

This proven senior leadership team brings its experience in multiple therapeutic areas and novel modalities, to ensure ophthalmic innovation translates to patient benefit.

Amber Ophthalmics is positioned for continued growth through development program acquisition, in-licensing and partnering of early development through Phase 3 assets.

​​